Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
103 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth analysis on Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong

  
Source:
Document ID
GMDHC0404TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Overview101
Therapeutics Development114
  Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Stage of Development111
  Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Therapy Area121
  Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Indication132
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Companies175
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Products under Development by Universities/Institutes222
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Therapeutics Assessment245
  Assessment by Monotherapy/Combination Products241
  Assessment by Mechanism of Action251
  Assessment by Route of Administration262
  Assessment by Molecule Type281
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Companies Involved in Therapeutics Development2918
  AB Science SA291
  Almirall, S.A.301
  Archer Pharmaceuticals, Inc.311
  Asana BioSciences, LLC321
  Celgene Corporation331
  F. Hoffmann-La Roche Ltd.341
  Genosco351
  Gilead Sciences, Inc.361
  GlaxoSmithKline Plc371
  Hutchison MediPharma Limited381
  Levolta Pharmaceuticals, Inc.391
  Merck KGaA401
  Millennium Pharmaceuticals Inc411
  Oscotec Inc.421
  Portola Pharmaceuticals, Inc.431
  Rigel Pharmaceuticals, Inc.441
  Taiho Pharmaceutical Co., Ltd.451
  TopiVert Ltd461
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Drug Profiles4738
  AB-8779 Drug Profile471
  ASN-002 Drug Profile481
  C-13 Drug Profile491
  CC-509 Drug Profile501
  cerdulatinib Drug Profile514
  entospletinib Drug Profile552
  fostamatinib disodium Drug Profile576
  GS-9876 Drug Profile631
  GSK-2646264 Drug Profile641
  HMPL-523 Drug Profile652
  LAS-189386 Drug Profile671
  nilvadipine Drug Profile682
  PRT-060318 Drug Profile701
  PRT-2761 Drug Profile711
  R-348 Drug Profile722
  RO-9021 Drug Profile741
  SKIO-592 Drug Profile751
  SKIO-703 Drug Profile761
  SKIO-703 Drug Profile771
  Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma Drug Profile781
  Small Molecule to Inhibit SYK for Inflammation Drug Profile791
  Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology Drug Profile801
  TAK-659 Drug Profile811
  TAS-5567 Drug Profile821
  TOP-1210 Drug Profile831
  TOP-1630 Drug Profile841
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Dormant Projects855
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Discontinued Products901
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) Featured News &Press Releases9111
  Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings911
  May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease921
  Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016921
  Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP931
  Mar 18, 2016: Asana BioSciences, to Provide Update on ASN002, a Novel SYK/JAK Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies931
  Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia941
  Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP941
  Jan 15, 2016: Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia951
  Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco951
  Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition961
  Nov 30, 2015: Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor, at American Society of Hematology Annual Meeting971
  Oct 30, 2015: Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers971
  Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP981
  May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib982
  May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting1002
Appendix1022
  Methodology1021
  Coverage1021
  Secondary Research1021
  Primary Research1021
  Expert Panel Validation1021
  Contact Us1021
  Disclaimer1031

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-SYK-Spleen-Tyrosine-Kinase-or-p72-Syk-or-SYK-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16286>
  
APA:
Global Markets Direct - Market Research. (2016). Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-SYK-Spleen-Tyrosine-Kinase-or-p72-Syk-or-SYK-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16286>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.